Gonadal steroid binding globulin

Men with metastatic prostate cancer (leuprolide acetate suspension [Lupron Depot ]): Hot flushes, 100 121 180 187 190 impotence, 100 180 190 decreased libido, 100 180 testicular atrophy, 100 180 190 general pain, 100 180 187 190 GI disorders, 100 187 190 edema, 100 187 190 injection site reaction, 180 187 190 urinary disorder, 100 180 187 190 respiratory disorder, 100 190 infection, 100 joint disorder, 180 187 190 peripheral edema, 99 100 116 190 asthenia, 100 190 fatigue/lethargy. 190

The secretion of hypothalamic, pituitary, and target tissue hormones is under tight regulatory control by a series of feedback and feed- forward loops. This complexity can be demonstrated using the growth hormone (GH) regulatory system as an example. The stimulatory substance growth hormone releasing hormone (GHRH) and the inhibitory substance somatostatin (SS) both products of the hypothalamus, control pituitary GH secretion. Somatostatin is also called growth hormone-inhibiting hormone (GHIH). Under the influence of GHRH, growth hormone is released into the systemic circulation, causing the target tissue to secrete insulin-like growth factor-1, IGF-1. Growth hormone also has other more direct metabolic effects; it is both hyperglycemic and lipolytic. The principal source of systemic IGF-1 is the liver, although most other tissues secrete and contribute to systemic IGF-1. Liver IGF-1 is considered to be the principal regulator of tissue growth. In particular, the IGF-1 secreted by the liver is believed to synchronize growth throughout the body, resulting in a homeostatic balance of tissue size and mass. IGF-1 secreted by peripheral tissues is generally considered to be autocrine or paracrine in its biological action.

Gonadal steroid binding globulin

gonadal steroid binding globulin


gonadal steroid binding globulingonadal steroid binding globulingonadal steroid binding globulingonadal steroid binding globulingonadal steroid binding globulin